你目前无法使用部分二次筛选功能
请联系客服开通更多权限和功能！
| 药品名称 | 剂型 | USP 溶出方法 | 转速（转/min） | 溶出介质 | 容积 | 推荐采样时间 | 更新时间 | 查看详情 |
|---|---|---|---|---|---|---|---|---|
| Methyldopa | Tablet | II (Paddle) | 50 | 0.1 N HCl | 900 | 10, 15, 30 and 45 | 2025-01-17 | 查看 |
| Etrasimod Arginine | Tablet | II (Paddle) | 75 | 50 mM Phosphate buffer w/0.2% Tween 20, pH 6.8 | 900 | 5, 15, 20, 30 and 45 | 2024-11-15 | 查看 |
| Valbenazine | Capsule (Sprinkle) | I (Basket) | 50 | 0.1 N HCl | 900 | 5, 15, 20, 30 and 45 | 2024-11-15 | 查看 |
| Acalabrutinib Maleate | Tablet | II (Paddle) | 75 | 5 Mm Phosphate buffer, pH 6.8 | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2024-11-01 | 查看 |
| Allopurinol | Suspension | II (Paddle) | 75 | 0.01 N HCl | 900 | 10, 20, 30, 40, 50 and 60 | 2024-11-01 | 查看 |
| Aripiprazole | Suspension (Extended Release) | IV (Flow through Cell) with closed system | 4 mL/min | Acetate buffer, pH 5.0 | 1000 | 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 14, 16 and 18 hours | 2024-11-01 | 查看 |
| Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate | Tablet | II (Paddle) | 75 | 50 mM Citrate buffer, pH 5.5 | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2024-11-01 | 查看 |
| Buspirone Hydrochloride | Capsule | II (Paddle) | 50 | 0.01 N HCl | 500 | 10, 20, 30 and 45 | 2024-11-01 | 查看 |
| Clonazepam | Suspension | Develop a dissolution method | 2024-11-01 | 查看 | ||||
| Estradiol | Vaginal Insert | III (Reciprocating Cylinder) | 30 dips/min | 0.1 N HCl with 0.5% SLS | 250 | 30, 60, 90 and 120 | 2024-11-01 | 查看 |
| Levetiracetam (1 g and 1.5 g) | Tablet (Extended Release) | III (Reciprocating Cylinder) | 15 dips/min | Sodium acetate buffer, pH 4.5 | 900 | 1, 2, 4, 6, 8, 10 and 12 hours | 2024-11-01 | 查看 |
| Memantine HCl | Tablet (Orally Disintegrating) | I (Basket) | 100 | 0.1 N HCl | 900 | 15, 30, 25 and 60 | 2024-11-01 | 查看 |
| Palovarotene | Capsule | II (Paddle) with sinkers | 50 | 5 mM Phosphate buffer, pH 8.0 with 0.5% SLS | 900 | 5, 10, 15, 30, 45 and 60 | 2024-11-01 | 查看 |
| Quizartinib Dihydrochloride | Tablet | II (Paddle) | 50 | 0.1 N HCl | 900 | 15, 20, 30, 45, and 60 | 2024-11-01 | 查看 |
| Ritlecitinib Tosylate | Capsule | Refer to FDA's Dissolution Guidance, 2018 | 2024-11-01 | 查看 | ||||
| Resmetirom | Tablet | Develop a dissolution method | 2024-09-03 | 查看 | ||||
| Cenobamate | Tablet | Refer to FDA's Dissolution Guidance, 2018 | 2024-08-05 | 查看 | ||||
| Fezolinetant | Tablet | Refer to FDA's Dissolution Guidance, 2018 | 2024-08-05 | 查看 | ||||
| Leniolisib Phosphate | Tablet | I (Basket) | 100 | Acetate Buffer, pH 4.0 | 900 | 10, 20, 30, 40, 50, 60, 70 and 80 | 2024-08-05 | 查看 |
| Macitentan (MAC); Tadalafil (TAD) | Tablet | II (Paddle) | 60 | MAC: 0.05 M sodium phosphate buffer, pH 5.5 with 0.30% (w/v) CTAB; (TAD):0.05 M sodium phosphate buffer, pH 6.8 with 3.0% (w/v) polysorbate 20 | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2024-08-05 | 查看 |
